Table 5.

Payers’ views on MCED's potential impact on disparities and whether this will be considered in coverage decisions.

Aspect	Percent (n/N) of payers expressing this view (N = 19)
Does MCED testing have the potential to address barriers to screening?
Yes	68 (13/19)
No	32 (6/19)
Does MCED testing have the potential to reduce disparities?
Yes	26 (6/19)
No	74 (14/19)
Reasons why MCED testing will not reduce disparities a
Harm and financial burden from overdiagnosis or overtreatment will disproportionately impact people with disparities	47 (9/19)
Access to an MCED test will not resolve barriers to other needed care	37 (7/19)
Coverage of MCED testing by private payers and employers will not address disparities in an uninsured or Medicaid population	16 (3/19)
Would disparity considerations impact coverage decisions for MCED testing?
Yes	58 (11/19)
If MCED is clinically proven	21 (4/19)
If MCED demonstrates reduction in disparities	16 (3/19)
If logistical barriers to access for downstream care are addressed	21 (4/19)
No	42 (8/19)
Once the test is proven, it should be covered for all patients	26 (5/19)
Policies are based on clinical benefit for all. It is not legally possible to structure a policy based on social determinants of health	16 (3/19)

Note: MCED = multicancer early-detection.

^aDoes not amount to 100% as some payers cited multiple reasons.